Metabolic Panel Assays
BioMark Liquid Biopsy Metabolic Panel Assays
BioMark has invested and successfully discovered and validated a new high-powered metabolic panel assay for early diagnosis of Lung Cancer. This performance panel assay has clinically demonstrated superior detection capabilities for early stage I / II Lung Cancers using urine and plasma. This is a major breakthrough in Lung Cancer diagnostics and strategically positions the company in a vintage position for high risk lung cancer screening market which currently uses low dose CT scans (LDCT). ML being incorporated in the analysis of the assay.